Microglia response and P2 receptor participation in oxygen/glucose deprivation-induced cortical damage.
In the present work, we used a unique cortical/striatal/subventricular zone organotypic model in order to analyze the role of resident microglia in oxygen/glucose deprivation and to check the presence and modulation of several P2 receptors in the cortex. Immunofluorescence with the microglial marker OX42 and pharmacological experiments with indomethacin indicate that activation and recruitment of microglia after the insult is linked to cellular loss, mainly in the cortex. The confocal analysis with OX42 shows that, among the P2 receptors tested, P2X4, and P2X7 are expressed on microglia, while P2X1 and P2Y(1-2-12), although present in the slices, did not co-localize, whereas P2X6 is not detected. The upregulation of P2X4 and P2X7 on microglia and the toxic effect that different P2 agonists exert on cortical slices during oxygen/glucose deprivation indicate that a purinergic mechanism is related to the microglia activity; the protective effect of the P2 antagonist TNP-ATP is also described. In order to better understand the relationship between P2 receptors and OGD-activated microglia, we induced oxygen/glucose deprivation in co-cultures of organotypic slices and N9 microglia cell line. The presence of the N9 (which expresses P2X4 and P2X7 protein) in the cultures increases the damage in the cortex by 40% and the use of P2 antagonist PPADS reduced the cell damage due to the N9 activation. Our results show that microglia recruitment after a metabolic impairment is associated with cellular loss and that P2X4 and P2X7, are involved in microglia activity. The neuroprotective action exerted by TNP-ATP and PPADS and the possible use of purinergic antagonist in the pharmacological treatment of oxygen/glucose deprivation is also addressed.
Cavaliere
F
F
Research Institute for Applied Neuroscience, FAN GmbH, Leipziger Str., 44, D-39120 Magdeburg, Germany. f.cavaliere@nsantalucia.it
Dinkel
K
K
Reymann
K
K
D000255:Adenosine Triphosphate / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D015153:Blotting, Western / Q000379:methods; D001927:Brain Diseases / Q000209:etiology* / Q000473:pathology; D039481:CD11b Antigen / Q000378:metabolism; D016923:Cell Death / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000473:pathology*; D005455:Fluorescent Antibody Technique / Q000379:methods; D005947:Glucose / Q000172:deficiency*; D000860:Hypoxia / Q000150:complications*; D017628:Microglia / Q000187:drug effects / Q000502:physiology*; D018613:Microscopy, Confocal / Q000379:methods; D009924:Organ Culture Techniques / Q000379:methods; D051381:Rats; D018048:Receptors, Purinergic P2 / Q000502:physiology*
D039481:CD11b Antigen; D018048:Receptors, Purinergic P2; D000255:Adenosine Triphosphate; D005947:Glucose